Depression in children and young people: identification and management NICE guidelines

Prevalence, progress, and subgroup disparities in pharmacological antidepressant treatment of those who screen positive for depressive symptoms: A repetitive cross-sectional study in 19 European countries

“…53 , 54 However, UK clinical guidelines advise psychological therapies as the first-line treatment, unless depression is severe, for those under 18 years old. 55 There is a great deal of media and policy attention to mental health in young people, a mental health workforce shortage, and consequent referral pressures impeding access to child and adolescent mental health services. 56 We lacked data on younger age groups from other European countries, but access to child and adolescent mental health services is also sometimes suboptimal in other European countries.…”

Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol

“…Additionally, according to the NICE and CANMAT 2016 guidelines, sertraline is the recommended second-line treatment. And it is also the most commonly used medicine in public hospitals in China [ 7 , 8 , 25 ]. Duloxetine was chosen based on our previous meta-analysis, which indicated that it has one of the highest likelihoods of being ranked as the most effective [ 26 ].…”

“…Whether fluoxetine or fluoxetine combined with cognitive-behavioural therapy (CBT) is better for treating adolescent MDD remains controversial. The guidelines provided by the National Institute of Clinical Excellence (NICE) in the United Kingdom explicitly recommend prescribing fluoxetine only in conjunction with psychotherapy [ 7 ], but the depression practice parameters of the American Academy of Child and Adolescent Psychiatry (AACAP) suggest administration of fluoxetine alone is also a reasonable strategy, and offers no preferred for monotherapy versus combined treatment [ 6 ]. Moreover, the Guidelines for Adolescent Depression in Primary Care (GLAD-PC) and Canadian Network for Mood and Anxiety Treatment (CANMAT) recommend combination therapy after patients demonstrate that they are unresponsive to fluoxetine monotherapy [ 8 , 9 ].…”

The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines

“…Furthermore, BAP 2015 [ 17 ], recommended that ADs are not a first-line treatment for major depression in children and adolescents, and AD treatment should be considered only when there has been a partial or no response to other treatments such as CBT or IPT, where depression is severe, or when there is a history of moderate-to-severe recurrent depression. In recent CPGs for depression in children and young people [ 64 ], psychological therapy including CBT, non-directive supportive therapy, and IPT was recommended for mild depression in children and adolescents. For moderate-to-severe depression, the NICE guidelines [ 64 ] recommended psychological therapy initially; combined treatment of fluoxetine and psychological therapy could be considered as initial treatment for moderate-to-severe depression in young people (12−18 years).…”

“…In recent CPGs for depression in children and young people [ 64 ], psychological therapy including CBT, non-directive supportive therapy, and IPT was recommended for mild depression in children and adolescents. For moderate-to-severe depression, the NICE guidelines [ 64 ] recommended psychological therapy initially; combined treatment of fluoxetine and psychological therapy could be considered as initial treatment for moderate-to-severe depression in young people (12−18 years). Sertraline and citalopram were limited to situations when patients and parents/caregivers have been informed fully, the depression is sufficiently severe, and there has been a reasonable effort to try combination treatment of fluoxetine and psychological therapy [ 64 ].…”